Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14388538 | 0.76 | ALDH1A1 (0.52) | ALDH1A1CYP3A4 | |
| SCHEMBL8827802 | 0.76 | ALDH1A1 (0.52) | ALDH1A1CYP3A4HSD11B1 | |
| SCHEMBL580581 | 0.76 | ALDH1A1 (0.72) | ALDH1A1CYP3A4 | |
| SCHEMBL9642004 | 0.76 | ALDH1A1 (0.72) | ALDH1A1CYP3A4 | |
| SCHEMBL21378 | 0.76 | ALDH1A1 (0.72) | ALDH1A1CYP3A4 | |
| SCHEMBL174369 | 0.76 | ALDH1A1 (0.72) | ALDH1A1CYP3A4 | |
| SCHEMBL19444447 | 0.76 | ALDH1A1 (0.72) | ALDH1A1CYP3A4 | |
| SCHEMBL247292 | 0.76 | — | — | |
| SCHEMBL22965210 | 0.75 | — | — | |
| SCHEMBL25403242 | 0.74 | ALDH1A1 (0.50) | ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001876-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4667461-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON S AND GAUCHER DISEASE | Children's Hospital Medical Center (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | CHILDRENS HOSPITAL MED CT (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| EP-4572761-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| CN-119730854-A | Compounds and their use as PDE4 activators | 米罗尼德有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024038129-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108059-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR | INCYTE CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | HRH4, HRH2, HRH1 | ALDH1A1 1903/4885CYP3A4 486/4885HSD11B1 2113/4885 |
| US-20260001876-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE4B, PDE7A | ALDH1A1 1240/4885CYP3A4 295/4885HSD11B1 209/4885 |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | HRH4, HRH2, HRH1 | ALDH1A1 2399/4885CYP3A4 86/4885HSD11B1 1868/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | ALDH1A1 474/4885CYP3A4 2220/4885HSD11B1 1751/4885 |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | ALDH1A1 989/4885CYP3A4 295/4885HSD11B1 212/4885 |
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | GBA1, GAA, GBA2 | ALDH1A1 1073/4885CYP3A4 1271/4885HSD11B1 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.